Before Switzerland became a hotbed for biopharma start-ups, the country was known for its strengths in manufacturing. In fact, there are currently 59 CDMOs with operations in Switzerland, according to the Swiss Biotech Association (SBA) directory.
One of these is ten23, a self-described “human-centric and sustainable” firm focused on producing sterile dosage forms. Its CEO and founder, Hanns-Christian Mahler, previously headed up pharmaceutical development and supplies at pharma major Roche Holding AG for ten years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?